Esperion Therapeutics (ESPR) PT Raised to $65 at Chardan Capital Markets Jan 31, 2020 10:52AM
Esperion Therapeutics (ESPR) PT Raised to $100 at Chardan Capital Markets Mar 27, 2018 03:33PM
Esperion Therapeutics (ESPR) PT Raised to $75 at Chardan Capital Markets; Positive Bias Dec 5, 2017 04:26PM
Pre-Open Movers 02/03: (PXLW) (DATA) (PTN) Higher; (DECK) (IDXG) (FEYE) (GPRO) (AMZN) Lower (more...) Feb 3, 2017 09:29AM
Chardan Capital Cautious on Esperion (ESPR) Partnership Ahead of Phase 3 Data Jan 8, 2016 09:51AM


Dec 7, 2015 08:28AM Chardan Capital No Longer Expects Underperformance from Orexigen Therapeutics (OREX)
Oct 12, 2015 01:01PM Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002
Sep 30, 2015 10:45AM Notable Analyst Rating Changes 9/30: (RF) (CP) (ESPR) Upgraded; (GPS) (GPC) (ITC) Downgraded
Sep 30, 2015 09:32AM Pre-Open Stock Movers 09/30: (EZCH) (RENT) (WDC) Higher; (CUDA) (PLNT) (VRNT) Lower (more...)
Sep 30, 2015 09:31AM UPDATE: Chardan Upgrades Esperion (ESPR) to Neutral But Maintains Negative Bias
Sep 29, 2015 06:46AM Chardan Capital Cuts PT on Esperion Therapeutics (ESPR) to $29; EOP2 Minutes Worse than Expected
Aug 31, 2015 08:12AM Chardan Trims PT on Esperion (ESPR) to $36 as Negatives Continue Increasing
Aug 18, 2015 08:17AM Chardan Capital Affirms Esperion (ESPR) at 'Sell'; Bear Case Confirmed, CVOT Needed for P2 Indications
Aug 7, 2015 08:30AM Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
Jul 31, 2015 10:44AM Chardan Capital Boosts PT on Esperion (ESPR) to $45; New Disclosure Does Not Reveal Higher Rate of SAEs for ETC-1002
Jul 27, 2015 08:31AM Esperion Therapeutics (ESPR) PT Cut to $40 at Chardan Capital Markets
Jul 8, 2015 08:19AM Chardan Capital Says Esperion Therapeutics (ESPR) Concerns 'Unanswered' Despite Lifting of FDA Hold
Jul 7, 2015 09:30AM Pre-Open Stock Movers 07/07: (DEPO) (PBMD) (PNK) Higher; (ETRM) (AMD) (SHLM) Lower (more...)
Jun 10, 2015 10:06AM Esperion Therapeutics (ESPR) Price Target Lowered to $50 at Chardan
May 22, 2015 10:25AM Notable Analyst Rating Changes 5/22: (RWLK) (BAH) (DOV) Upgraded; (GD) (JGW) (CONN) Downgraded
May 22, 2015 08:11AM Chardan Capita Starts Esperion Therapeutics (ESPR) at Sell; Post-IPO Run Leads to Unfavorable Risk-Reward
May 22, 2015 08:09AM Chardan Capital Markets Starts Esperion Therapeutics (ESPR) at Sell